REPL INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead the Replimune Class Action Lawsuit
SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Replimune Group, Inc. (NASDAQ: REPL) publicly traded securities between November 22, 2024 and July 21, 2025, inclusive (the “Class Period”), have until September 22, 2025 to seek appointment as lead plaintiff of the Replimune class action lawsuit. Captioned Jboor v. Replimune Group, Inc., No. 25-cv-012085 (D. Mass.), the Replimune class action lawsuit charges Replimune and certain of Replimune’s top executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Replimune class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-replimune-group-inc-class-action-lawsuit-repl.html
You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com.
CASE ALLEGATIONS: Replimune is a clinical-stage biotechnology company that focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. Replimune’s lead product candidate is RP1 (vusolimogene oderparepvec), according to the complaint.
The Replimune class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that defendants recklessly overstated Replimune’s IGNYTE trial’s prospects, given material issues that defendants knew or should have known of, which resulted in the U.S. Food and Drug Administration (“FDA”) deeming the IGNYTE trial inadequate and not well-controlled.
The Replimune class action lawsuit further alleges that on July 22, 2025, Replimune revealed that the FDA “issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1” and “is unable to approve the application in its present form,” indicating “that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.” On this news, the price of Replimune stock fell more than 77%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Replimune publicly traded securities during the Class Period to seek appointment as lead plaintiff in the Replimune class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Replimune class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Replimune class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Replimune class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
https://www.rgrdlaw.com/services-litigation-securities-fraud.html
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Contact:
Robbins Geller Rudman & Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
info@rgrdlaw.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
